Hexham, UK, April 2022: RareCan, a direct-to-patient clinical trial recruitment platform bringing together the power of patients and their data to reduce the costs of cancer trials for the global pharmaceutical industry, has appointed Raj Sharma as their Chief Technology Officer. Previously CTO at digital diagnostics company Mentis Cura, Raj brings with him a depth of knowledge in health technologies, cyber security and AI.
RareCan is bringing together a wealth of clinical, histological and genetic data about its members which presents huge opportunities to leverage advances in data science and machine learning to reduce the cost and increase the speed of delivering clinical trials in increasingly stratified groups of patients.
Piers Kotting, CEO RareCan commented, ‘We are delighted to welcome Raj to the RareCan team at such an exciting time for RareCan. With our proof of concept now delivered and our first contract underway, Raj’s skills and experience will be critical in driving forwards the development of our platform and growth of our business .’
Raj Sharma, Chief Technology Officer added, ‘I am delighted to join a pioneering and purposeful business, and am confident that I can add significant value and enhance the experience for everyone within the RareCan Community.’
Raj’s appointment comes as RareCan successfully closes its second seed funding round.